HC Wainwright Has Pessimistic View of BioNTech Q3 Earnings

BioNTech SE Sponsored ADR (NASDAQ:BNTX) – Investment analysts at HC Wainwright dropped their Q3 2025 EPS estimates for BioNTech in a research note issued to investors on Wednesday, June 25th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($1.12) per share for the quarter, down from their previous estimate of ($1.10). HC Wainwright currently has a “Buy” rating and a $138.00 target price on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for BioNTech’s Q1 2026 earnings at ($2.24) EPS, Q2 2026 earnings at ($2.27) EPS and FY2026 earnings at ($4.32) EPS.

BNTX has been the topic of a number of other reports. JPMorgan Chase & Co. cut their price objective on shares of BioNTech from $120.00 to $116.00 and set a “neutral” rating on the stock in a research note on Thursday, May 22nd. Truist Financial restated a “buy” rating and set a $155.00 price objective (up previously from $151.00) on shares of BioNTech in a report on Tuesday, June 3rd. BMO Capital Markets boosted their price objective on BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a report on Tuesday, March 11th. Citigroup reaffirmed a “buy” rating and set a $140.00 target price (down previously from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $171.44 target price on shares of BioNTech in a research note on Tuesday, March 11th. Five research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, BioNTech presently has an average rating of “Moderate Buy” and a consensus target price of $137.86.

BioNTech Stock Performance

Shares of BNTX opened at $106.72 on Friday. BioNTech has a 1 year low of $76.53 and a 1 year high of $131.49. The firm has a fifty day moving average of $102.79 and a 200-day moving average of $107.14. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.02 and a current ratio of 10.18. The company has a market cap of $25.65 billion, a price-to-earnings ratio of -31.39 and a beta of 1.29.

Institutional Trading of BioNTech

Several large investors have recently modified their holdings of the company. Bank of New York Mellon Corp boosted its position in shares of BioNTech by 4.3% in the fourth quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company’s stock valued at $419,000 after acquiring an additional 150 shares during the period. QRG Capital Management Inc. acquired a new position in BioNTech during the fourth quarter worth $275,000. SVB Wealth LLC acquired a new position in BioNTech during the fourth quarter worth $204,000. Jones Financial Companies Lllp increased its stake in shares of BioNTech by 110.3% in the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock valued at $53,000 after buying an additional 246 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in shares of BioNTech in the fourth quarter valued at $391,000. 15.52% of the stock is owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.